Stem-cell therapy for bronchopulmonary dysplasia.

Area of Science:

• Neonatal Medicine
• Regenerative Medicine
• Pulmonary Biology

Background:

• Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting premature infants.
• Current treatments for BPD are limited, highlighting the need for novel therapeutic strategies.
• Mesenchymal stem/stromal cells (MSCs) are being investigated for their potential to treat BPD.

Purpose of the Study:

• To review the preclinical evidence supporting MSC therapy for BPD.
• To understand the mechanisms by which MSCs exert therapeutic effects in BPD models.
• To evaluate the role of MSC-derived exosomes in BPD treatment.

Main Methods:

• Review of preclinical studies using rodent hyperoxia models of BPD.
• Analysis of the anti-inflammatory and proangiogenic properties of MSCs.
• Investigation of the therapeutic potential of MSC-derived exosomes.

Main Results:

• MSCs demonstrate proangiogenic effects in rodent BPD models, largely mediated by vascular endothelial growth factor.
• MSCs modulate endogenous lung cells, shifting the balance from inflammation to a prohealing phenotype.
• MSC-derived exosomes can replicate the beneficial effects of MSCs in BPD models.

Conclusions:

• Preclinical data strongly support the therapeutic potential of MSCs and their exosomes for BPD.
• Understanding these mechanisms is crucial for evaluating ongoing clinical trials of MSC therapy for BPD.
• MSC-based therapies offer a promising avenue for treating BPD in neonates.